Stem Cell Transplant Conditioning Without Genotoxic Myeloablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for hematopoietic cell transplantation, such as myeloablative conditioning regimens, involve high toxicity due to radiation and chemotherapy, limiting their clinical utility and causing adverse effects on patients.
Innovation Solution
A non-myeloablative, non-genotoxic conditioning regimen using agents like anti-c-kit antibodies and CD47 blockers, combined with transient immunosuppression, to deplete endogenous stem cells and facilitate engraftment of exogenous hematopoietic stem cells without causing long-lasting pancytopenia or toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myeloablative conditioning regimens (radiation and chemotherapy) are used to clear bone marrow niches, then engraftment of donor stem cells is achieved, but severe toxicity and adverse effects occur
Solution Approach 1:
The patent extracts and removes the toxic radiation and chemotherapy components from the conditioning regimen, replacing them with non-myeloablative agents that clear bone marrow niches without causing severe toxicity. This allows engraftment to proceed while eliminating the harmful effects of traditional myeloablative approaches.
Solution Approach 2:
The patent changes the parameters of the conditioning regimen by using non-myeloablative doses and non-genotoxic agents instead of high-dose radiation and chemotherapy. This parameter change maintains the ability to clear niches for engraftment while reducing toxicity to acceptable levels.
2Object-affected harmful factors
If non-myeloablative conditioning is used to reduce toxicity, then patient safety improves, but engraftment efficiency decreases
Solution Approach 1:
The patent applies preliminary action by administering non-myeloablative conditioning agents before stem cell infusion to pre-clear bone marrow niches and create a receptive environment. This preliminary preparation ensures efficient engraftment occurs without requiring toxic myeloablative doses.
Solution Approach 2:
The patent introduces intermediary agents that facilitate the transition from non-myeloablative conditioning to successful engraftment. These agents mediate between the reduced-intensity conditioning and the stem cell infusion, ensuring efficient engraftment without toxicity.
3Object-generated harmful factors
If high-dose chemotherapy is administered to treat malignancies, then cancer eradication is achieved, but bone marrow function is destroyed
Solution Approach 1:
The patent extracts the bone marrow-destructive component from high-dose chemotherapy, using non-myeloablative agents that eradicate malignancies without destroying bone marrow function. This allows cancer treatment while preserving the ability of the bone marrow to support engraftment.
Solution Approach 2:
The patent converts the harmful effect of chemotherapy on bone marrow into a benefit by using selective non-myeloablative agents that target malignancies while sparing normal bone marrow cells. This transforms the previously harmful myeloablation into a controlled, non-destructive process that facilitates engraftment.
Data Source
AI summary
The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection.